Citius Oncology, Inc. (CTOR) carries a DilutionWatch risk score of 71/100 — placing it in the HIGH tier. This score is calculated from real SEC filing data including shelf registration capacity, ATM program activity, warrant overhang, cash runway, and historical dilution patterns.
A score of 71/100 indicates several significant dilution risk factors. Investors should monitor SEC filings closely and consider position sizing carefully.
The DilutionWatch composite score weighs five key factors pulled directly from SEC EDGAR filings. Here's what's contributing to CTOR's elevated score:
Companies file S-3 "shelf" registrations to pre-authorize future securities offerings. The size of registered but unissued shares relative to market cap is one of the strongest predictors of future dilution. DilutionWatch tracks active shelf capacity for CTOR in real time — any 424B5 prospectus supplement filed against the shelf signals an imminent offering.
At-The-Market (ATM) programs allow companies to drip-sell shares into the open market daily without a formal offering announcement. If CTOR has an active ATM program (identified by 424B3 filings referencing a "Sales Agreement"), shares are being continuously issued. This creates persistent downward pressure with no clear end date.
Outstanding warrants and convertible notes represent shares that haven't been issued yet but will be — often at a discount to market price. A high warrant coverage ratio (warrants outstanding as a % of current share count) caps any rally and guarantees future dilution when the instruments are exercised or converted.
How long can CTOR operate without raising new capital? DilutionWatch estimates cash runway from the most recent 10-Q balance sheet and quarterly burn rate. Companies in the oncology space with under 6 months of runway almost always raise capital through equity — meaning more shares.
The share count history doesn't lie. DilutionWatch tracks how many times CTOR has increased shares outstanding, whether it has a reverse split history, and the rate of share count growth over 1, 2, and 3 years. Serial diluters almost always dilute again.
The CTOR score updates automatically as new SEC filings appear — typically within 60 seconds of EDGAR publication. The score you see on the CTOR live page reflects the most current filing data.
Given CTOR's high risk score, the filings most worth watching are:
Among cancer immunotherapy and oncology drug companies, dilution events occur more frequently than in large-cap markets because many of these companies operate with negative cash flow and limited access to traditional debt financing. Capital raises through equity offerings are a standard part of the business model — which means understanding when and how much is critical for position management.
The key difference between manageable dilution and portfolio-destroying dilution is usually the terms: a well-structured registered offering at a modest discount is very different from a toxic convertible note with a floating conversion price. DilutionWatch parses the actual filing language to flag the difference.
DilutionWatch monitors CTOR and 10,000+ other tickers with 60-second EDGAR polling. Add CTOR to your watchlist and get alerted the moment a dilution filing appears — before the stock reprices.
Set Up CTOR Alert Free →A score of 71 places CTOR in the high tier of dilution risk across all 10,000+ tickers tracked by DilutionWatch. It means several significant risk factors have been identified. Investors should treat this as a signal to monitor the stock closely, not necessarily to sell immediately.
The score updates automatically when new SEC filings appear. DilutionWatch polls EDGAR every 60 seconds. Most filings appear in the DilutionWatch database within 1-3 minutes of being published by the SEC.
All CTOR filings are available at SEC EDGAR. DilutionWatch provides parsed alerts and risk scoring on top of the raw filings.